Antenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program

Simple item page
dc.contributor.authorKeir, A.
dc.contributor.authorRumbold, A.
dc.contributor.authorShepherd, E.
dc.contributor.authorMcintyre, S.
dc.contributor.authorGroves, C.
dc.contributor.authorCavallaro, A.
dc.contributor.authorCrowther, C.
dc.contributor.authorCallander, E.
dc.date.issued2022
dc.descriptionFirst published: 29 November 2021
dc.description.abstractPrevious work demonstrated that implementing a quality improvement (QI) program improves the uptake of guideline-recommended antenatal magnesium sulphate, a critical intervention known to reduce cerebral palsy risk. Here we estimate potential cost savings attributable to the improved uptake. By expanding coverage from 63 to 83% of eligible women, we estimated that five children potentially would not have received a diagnosis of cerebral palsy, a potential cost saving of $AU4.8 million in lifetime healthcare costs. Our findings strengthen the case for embedding QI approaches in perinatal care to reduce the incidence of cerebral palsy.
dc.description.statementofresponsibilityAmy Keir, Alice Rumbold, Emily Shepherd, Sarah Mcintyre, Charlotte Groves, Angela Cavallaro, Caroline Crowther, and Emily Callander
dc.identifier.citationAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2022; 62(1):168-171
dc.identifier.doi10.1111/ajo.13459
dc.identifier.issn0004-8666
dc.identifier.issn1479-828X
dc.identifier.orcidKeir, A. [0000-0003-1692-5676]
dc.identifier.orcidRumbold, A. [0000-0002-4453-9425]
dc.identifier.orcidShepherd, E. [0000-0002-9669-788X]
dc.identifier.orcidCrowther, C. [0000-0002-9079-4451]
dc.identifier.urihttps://hdl.handle.net/2440/133826
dc.language.isoen
dc.publisherWiley
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1161379
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1159536
dc.rights© 2021 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists
dc.source.urihttps://doi.org/10.1111/ajo.13459
dc.subjectmagnesium sulphate
dc.subjectcerebral palsy
dc.subjectquality improvement
dc.subjectcost-benefit analysis
dc.titleAntenatal magnesium sulphate for preventing cerebral palsy: An economic evaluation of the impact of a quality improvement program
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Obstetrics and Gynaecology publications